reduce of facial skin elasticity in healthy volunteers
Conditions
Interventions
Group 1: Application of 4 ml cell-free Exokine® derived Serum (EdS) in week 0, 2, 4 and 6 via mesotherapy gun in facial skin
Group 2: Application of 4 ml cell-free Exokine® derived Serum (EdS) in week
Sponsors
Center for molecular orthopaedics and regenerative medicine (CEMOR)
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. 30-65 years old females and males; 2. Apparent loss of facial skin elasticity; 3. Signed informed written Patient Informed Consent Form;
Exclusion criteria
Exclusion criteria: 1. Severe skin diseases eg psoriasis, atopic eczema (neurodermatitis) or other autoimmune skin diseases; 2. Skin cancer in the anamnesis; 3. Systemic diseases with skin involvement (SLE); 4. Pre-treatment with laser, Botulinum Toxin or hyaluronic acid (HA) in the tested area. 5. Recently started diet (less than 3 months) or nutritional supplementary (less than 3 years); 6. Any kind of acute infection; 7. Chronic Acne; 8. Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of the „Global Aesthetic Improvement Scale“ (GAIS) between baseline and week 12 and baseline and week 24. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the questionnaire "Patients Attractivity Self-Estimation Score" between baseline and week 12 and baseline and week 24. Collection of adverse reactions of cell-free Exokine® derived Serum (EdS) over the whole period of the trial. | — |
Countries
Germany
Contacts
Public ContactNancy Safaian
Center for molecular orthopaedics and regenerative medicine (CEMOR)
Outcome results
None listed